Pectin Intervention Study and Long-term Follow-up in Lipid Transfer Proteins Allergic Patients

Launched by FUNDACIÓN PÚBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD · Aug 14, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of pectins, which are natural dietary fibers, on patients who have allergies to certain foods, particularly peaches. Researchers believe that pectins can help improve the gut's bacteria balance and boost the immune system, potentially making it easier for allergic patients to tolerate foods they usually react to. Early findings suggest that after two months of taking pectins, patients showed better tolerance to peaches compared to those who received a placebo (a harmless pill with no active ingredients). The study will also look at how these effects last over time by checking participants’ reactions to peach and other allergens six months after they finish the pectin treatment.

To participate in this trial, you must be an adult who has a clear history of food allergy from eating peaches, confirmed by specific allergy tests. You should also be sensitized to a particular protein found in peaches. However, there are some conditions that would exclude you from participating, such as allergies to corn, active infections, or certain health issues like severe liver disease. If you join the trial, you will receive pectins or a placebo for two months and then be monitored for any changes in your allergy reactions and overall health. Remember, while this study may offer hope for improving food tolerance, it is still in the research phase and not yet recruiting participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults with a clear clinical history of food allergy after eating peach (oral allergy syndrome and/or systemic symptoms) and with or without clinical history of food allergy with peanut.
• • Sensitization to Pru p 3 by positive skin prick test (SPT wheal area \>7 mm2) and specific IgE (sIgE \>0.35 kUA/L)
• • Positive DBPCFC with peach juice.
• • If clinical history of food allergy with peanut, sensitization must be confirmed by positive SPT to peanut and sIgE \>0.35 kUA/L to Ara h 9 and clinical reactivity through a positive DBPCFC with peanut.
• • Signed informed consent.
• Exclusion Criteria:
• • Food allergy to corn.
• • Food allergy to peanut due to sensitization to storage proteins.
• • Previous/active treatment with sublingual immunotherapy to Pru p 3.
• • Pregnancy/lactation.
• • Active infections.
• • Inflammatory, autoimmune, and/or oncological diseases.
• • Severe immunodeficiency.
• • Metabolic syndrome.
• • Increased liver parameters and/or any liver disease.
• • Alcohol disorder.
• • Mental illness.
• • Mast cell activation syndrome.
• • Severe atopic dermatitis.
• • FEV1 \< 70%
• • Treatment with immunomodulators in the last five years.
• • Vitamin supplements, probiotics, prebiotics, antibiotics, metformin, statins, proton pump inhibitors, or corticosteroids in the last three months.
• • Any clinical condition contraindicating performance of DBPCFC.